Mark Vignola

Mark Vignola, Ph.D., serves as Chief Financial Officer of Terns Pharmaceuticals. Prior to joining Terns as its CFO, Dr. Vignola was most recently the Chief Financial Officer of Applied Therapeutics, a clinical-stage biopharmaceutical company. While at Applied Therapeutics, Dr. Vignola led the company’s initial public offering, private placement, and follow-on offering. Prior to joining Applied Therapeutics, Dr. Vignola was Head of Corporate Development & Investor Relations at Intercept Pharmaceuticals, during which time he was a top ranked healthcare executive in the 2019 Institutional Investor All-America Executive Team survey. Prior to joining Intercept in 2015, he was a member of the biotechnology equity research team at Needham & Company.

Dr. Vignola earned his Ph.D. in Molecular Genetics and Microbiology from Duke University and B.S. in Biology from Boston College.